𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Marek's disease: A natural model for the Landry-Guillain-Barré syndrome

✍ Scribed by Dr. Jack G. Stevens; Jay S. Pepose; Margery L. Cook

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
714 KB
Volume
9
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

The early lesions of Marek's disease in chickens are indistinguishable from those of the Landry-Guillain-BarrC syndrome in human beings. Because of these similarities, and since the etiological agent (a herpesvirus) is known, Marek's disease can be meaningfully exploited as a model of the Landry-Guillain-Barre syndrome. Recent work in our laboratories has shown that the agent establishes latent infections in neuronal supporting cells and that affected birds mount cellular and humoral immunological reactions to peripheral nerve and myelin. Based on these findings, a working hypothesis for the pathogenesis of the disease is presented.

📜 SIMILAR VOLUMES

A theory of virus-induced demyelination
A theory of virus-induced demyelination in the Landry-Guillain-Barré syndrome
✍ Jay S. Pepose 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 312 KB

The Landry-Guillain-Barré syndrome (LGBS) is a demyelinating disorder of the peripheral nervous system frequently preceded by infection with common viruses. Most prevalent among these agents are herpesviruses, particularly Epstein-Barr virus (EBV) and cytomegalovirus (CMV). The specific role played

The acute phase reactant, fibrinogen, as
The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome
✍ Rashmi Sanjay; Janice Flanagan; Donata Sodano; Kenneth C. Gorson; Allan H. Roppe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

The Guillian Barré syndrome is an acute inflammatory disorder for which plasma exchange is effective treatment. Up to 10% relapse after plasma exchange suggesting that treatment sometimes finishes before disease activity has resolved. We studied whether plasma fibrinogen, an inflammatory marker, mig

The First Total Synthesis of Ganglioside
The First Total Synthesis of Ganglioside GalNAc-GD1a, a Target Molecule for Autoantibodies in Guillain–Barré Syndrome
✍ Dr. Kohki Fujikawa; Shinya Nakashima; Miku Konishi; Tomoaki Fuse; Naoko Komura; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract The first synthesis of ganglioside GalNAc‐GD1a, featuring efficient glycan assembly and a cyclic glucosyl ceramide as a versatile unit for ganglioside synthesis is described. Although ganglioside GalNAc‐GD1a was first found as a brain ganglioside, IgG autoantibodies to GalNAc‐GD1a were

Is there a scientific rationale for ther
Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute guillain-barré syndrome?
✍ Robert Weinstein 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 836 KB

## IMMUNE MODULATION AND PLASMA EXCHANGE Transferable Serum Factors In 1971, Stuart Cook and colleagues reported that sera from 26 of 31 patients with Guillain-Barre syndrome caused complement-dependent demyelination of living

CSF protein biomarkers for proximal axon
CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome
✍ A. Petzold; J. Brettschneider; K. Jin; G. Keir; N.M.F. Murray; N.P. Hirsch; Y. I 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB

## Abstract Early predictors of prognosis in Guillain‐Barré syndrome (GBS) are needed to identify patients who are likely to make a poor recovery and to guide therapeutic decision‐making in the acute phase. Here we investigate whether axonal protein biomarkers released into the cerebrospinal fluid